Former Symphogen colleagues reunited in Norwegian biotech company

Former CEO of Symphogen Martin Olin, who has spearheaded Norwegian biotech company Bergenbio since September last year, can now greet a past colleague from Symphogen as Anders Tullgren steps in to chair Bergenbio.

Anders Tullgren and Martin Olin, past colleagues from their time at Symphogen, are reunited in the Norwegian biotech company Bergenbio, in which the former will be chair and the latter is CEO | Photo: Bergenbio / PR/Photographer: Nils Olav Mevatne -

CEO of Norwegian biotech company Bergenbio Martin Olin, who for a short time was a managing partner in venture capital firm Nordic Eye, will now be joined by a former colleague from his days at Symphogen, where Olin was in charge until October 2020 – few months after the company was sold for an estimated DKK 3bn (USD 455.7m) to French Servier.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs